Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications
Differentiated thyroid cancer (DTC) is a common and diverse endocrine malignancy. In most patients DTC results in an indolent and curable disease. Nevertheless, disease recurrence rates are relatively high (10%–30%), while 5% of the patients are resistant to conventional treatment and some of these...
Main Author: | Sagit Zolotov |
---|---|
Format: | Article |
Language: | English |
Published: |
Rambam Health Care Campus
2016-01-01
|
Series: | Rambam Maimonides Medical Journal |
Subjects: | |
Online Access: | http://rmmj.org.il/Pages/ArticleHTM.aspx?manuId=564 |
Similar Items
-
Influencers on Thyroid Cancer Onset: Molecular Genetic Basis
by: Berta Luzón-Toro, et al.
Published: (2019-11-01) -
Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer
by: Kinga Hińcza, et al.
Published: (2019-06-01) -
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
by: Woon Won Kim, et al.
Published: (2018-01-01) -
Somatic mutation testing: the role in differential diagnosis of thyroid neoplasms
by: Vera A. Kachko, et al.
Published: (2019-08-01) -
THE ROLE OF BRAF MUTATION STATUS IN SURGICAL TREATMENT OF WELL-DIFFERENTIATED THYROID CANCER
by: A. P. Polyakov, et al.
Published: (2017-04-01)